<DOC>
	<DOC>NCT00044031</DOC>
	<brief_summary>This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.</brief_summary>
	<brief_title>Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Inclusion criteria: Clinical diagnosis of pancreatic adenocarcinoma and unsuitable for pancreatic tumor resection Life expectancy of at least 3 months Functional status by Karnofsky Index of at least 70 Exclusion criteria: Prior treatment with chemotherapy, radiotherapy, or anticancer immunotherapy Chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease Immunodeficiency Bone marrow transplant within past year Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>G17DT</keyword>
	<keyword>gemcitabine</keyword>
</DOC>